Telos Capital Management Inc. Buys 547 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Telos Capital Management Inc. grew its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 3.1% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 18,174 shares of the pharmaceutical company’s stock after acquiring an additional 547 shares during the quarter. Telos Capital Management Inc.’s holdings in Vertex Pharmaceuticals were worth $8,811,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of the business. Capital World Investors boosted its position in shares of Vertex Pharmaceuticals by 5.7% during the 4th quarter. Capital World Investors now owns 28,325,695 shares of the pharmaceutical company’s stock valued at $11,406,667,000 after acquiring an additional 1,514,993 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Vertex Pharmaceuticals by 0.4% during the 4th quarter. Vanguard Group Inc. now owns 23,258,288 shares of the pharmaceutical company’s stock valued at $9,366,113,000 after acquiring an additional 98,654 shares during the last quarter. Capital Research Global Investors boosted its position in shares of Vertex Pharmaceuticals by 15.8% during the 4th quarter. Capital Research Global Investors now owns 10,428,951 shares of the pharmaceutical company’s stock valued at $4,199,713,000 after acquiring an additional 1,426,746 shares during the last quarter. Wellington Management Group LLP boosted its position in shares of Vertex Pharmaceuticals by 23.3% during the 4th quarter. Wellington Management Group LLP now owns 5,916,084 shares of the pharmaceutical company’s stock valued at $2,382,407,000 after acquiring an additional 1,117,214 shares during the last quarter. Finally, Loomis Sayles & Co. L P boosted its position in shares of Vertex Pharmaceuticals by 23.0% during the 4th quarter. Loomis Sayles & Co. L P now owns 3,772,789 shares of the pharmaceutical company’s stock valued at $1,519,302,000 after acquiring an additional 704,575 shares during the last quarter. Institutional investors own 90.96% of the company’s stock.

Vertex Pharmaceuticals Price Performance

VRTX opened at $478.96 on Thursday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.29 and a current ratio of 2.65. Vertex Pharmaceuticals Incorporated has a 52-week low of $377.85 and a 52-week high of $519.88. The stock has a market capitalization of $123.00 billion, a PE ratio of -122.18 and a beta of 0.41. The stock’s 50 day moving average price is $448.74 and its 200-day moving average price is $459.47.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings results on Monday, May 5th. The pharmaceutical company reported $4.06 earnings per share for the quarter, missing the consensus estimate of $4.29 by ($0.23). Vertex Pharmaceuticals had a negative net margin of 8.91% and a negative return on equity of 3.36%. The firm had revenue of $2.77 billion for the quarter, compared to the consensus estimate of $2.85 billion. During the same quarter in the prior year, the firm earned $4.76 earnings per share. The company’s revenue for the quarter was up 2.6% compared to the same quarter last year. On average, equities research analysts predict that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year.

Wall Street Analysts Forecast Growth

VRTX has been the topic of a number of research reports. Cantor Fitzgerald reissued an “overweight” rating and set a $535.00 price objective on shares of Vertex Pharmaceuticals in a report on Tuesday, May 6th. JPMorgan Chase & Co. raised their price objective on Vertex Pharmaceuticals from $512.00 to $515.00 and gave the company an “overweight” rating in a report on Tuesday, May 6th. Needham & Company LLC reissued a “hold” rating on shares of Vertex Pharmaceuticals in a report on Tuesday, May 6th. Royal Bank Of Canada set a $420.00 price objective on Vertex Pharmaceuticals and gave the company a “sector perform” rating in a report on Tuesday, June 17th. Finally, Scotiabank decreased their price objective on Vertex Pharmaceuticals from $450.00 to $442.00 and set a “sector perform” rating on the stock in a report on Tuesday, May 6th. Fourteen investment analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Vertex Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $511.62.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.